deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02857998

A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

Sponsor: Hutchison Medipharma Limited

Conditions Mature B-cell Neoplasms
Interventions HMPL-523
Updated 14 times since 2017 Last updated: Jul 15, 2024 Started: Dec 27, 2016 Primary completion: Jun 30, 2021 Completion: Sep 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Mature B-cell Neoplasms and is currently completed. Hutchison Medipharma Limited leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshot~May 2017 – ~Mar 2018 · 10 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Oct 2019 · 11 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Nov 2022 · 8 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1

    Status: Unknown → Completed

  3. Jul 2024 — Aug 2024 [monthly]

    Unknown PHASE1

    Status: Unknown Status → Unknown

  4. Nov 2022 — Jul 2024 [monthly]

    Unknown Status PHASE1

  5. Mar 2022 — Nov 2022 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

▶ Show 9 earlier versions

  1. Jan 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  2. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  3. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  4. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  5. Nov 2018 — Oct 2019 [monthly]

    Recruiting PHASE1

  6. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  7. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  8. May 2017 — Mar 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Jan 2017 — May 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hutchison Medipharma Limited
Data source: Hutchmed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations